NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
Clinical Trials
15 trialsNCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT01830270 2018-07-26
IPEC-GC
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT00176488 2017-03-23
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01123473 2016-10-12
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00003852 2016-06-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
UNICANCER
Phase 2 Terminated
NCT01985841 2015-10-08
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01167738 2015-04-24
PACT-17
IRCCS San Raffaele
Phase 2 Terminated
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00198172 2014-06-03
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Indiana University
Phase 2 Terminated
NCT01301040 2013-08-30
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
Jules Bordet Institute
Phase 2 Terminated
NCT00431795 2013-02-13
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00193024 2011-05-03
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00162812 2008-07-18
TOP
Jules Bordet Institute
Phase 2 Terminated